Provided by Tiger Trade Technology Pte. Ltd.

Astria Therapeutics Inc

12.58
0.0000
Volume:- -
Turnover:40.15M
Market Cap:718.13M
PE:-5.88
High:12.58
Open:12.58
Low:12.58
Close:12.58
52wk High:13.29
52wk Low:3.56
Shares:57.08M
Float Shares:38.38M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1381
EPS(LYR):-1.6784
ROE:-43.15%
ROA:-26.94%
PB:2.47
PE(LYR):-7.50

Loading ...

Company Profile

Company Name:
Astria Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.